ORIO, Francesco
 Distribuzione geografica
Continente #
NA - Nord America 19.366
EU - Europa 7.422
AS - Asia 2.358
Continente sconosciuto - Info sul continente non disponibili 62
OC - Oceania 20
SA - Sud America 8
AF - Africa 5
Totale 29.241
Nazione #
US - Stati Uniti d'America 19.345
UA - Ucraina 2.795
VN - Vietnam 1.476
GB - Regno Unito 1.157
SE - Svezia 1.106
DE - Germania 884
CN - Cina 707
FR - Francia 556
IT - Italia 376
FI - Finlandia 275
KR - Corea 126
PL - Polonia 109
EU - Europa 62
RU - Federazione Russa 38
NL - Olanda 24
BE - Belgio 21
AU - Australia 16
IE - Irlanda 16
CA - Canada 12
IN - India 11
DK - Danimarca 9
AT - Austria 5
BG - Bulgaria 5
ES - Italia 5
HR - Croazia 5
JP - Giappone 5
SG - Singapore 5
CZ - Repubblica Ceca 4
EG - Egitto 4
HU - Ungheria 4
IL - Israele 4
NZ - Nuova Zelanda 4
PA - Panama 4
PT - Portogallo 4
TR - Turchia 4
BR - Brasile 3
LU - Lussemburgo 3
MM - Myanmar 3
NO - Norvegia 3
RO - Romania 3
RS - Serbia 3
TW - Taiwan 3
BN - Brunei Darussalam 2
EE - Estonia 2
HK - Hong Kong 2
IM - Isola di Man 2
ME - Montenegro 2
MX - Messico 2
PE - Perù 2
AD - Andorra 1
AE - Emirati Arabi Uniti 1
AR - Argentina 1
CH - Svizzera 1
CL - Cile 1
CR - Costa Rica 1
CY - Cipro 1
DZ - Algeria 1
EC - Ecuador 1
GE - Georgia 1
GL - Groenlandia 1
GR - Grecia 1
ID - Indonesia 1
IR - Iran 1
KZ - Kazakistan 1
LI - Liechtenstein 1
MC - Monaco 1
MN - Mongolia 1
MO - Macao, regione amministrativa speciale della Cina 1
PH - Filippine 1
PK - Pakistan 1
SK - Slovacchia (Repubblica Slovacca) 1
TC - Turks e Caicos 1
Totale 29.241
Città #
Fairfield 2.739
Woodbridge 2.587
Houston 1.969
Dong Ket 1.474
Ann Arbor 1.448
Chandler 1.364
Ashburn 1.326
Wilmington 1.310
Seattle 1.081
Cambridge 933
Dearborn 890
Jacksonville 774
Southend 630
Nyköping 614
Beijing 303
Lawrence 258
Princeton 258
Boardman 194
Ogden 178
Düsseldorf 123
Des Moines 113
Kraków 108
San Diego 88
Bremen 74
Grafing 66
Nanjing 62
Jinan 55
London 47
Hefei 40
Edinburgh 28
Norwalk 27
Shenyang 27
New York 25
Kunming 24
San Mateo 24
Brussels 21
Helsinki 21
Napoli 21
Nanchang 20
Auburn Hills 18
Hanover 17
Guangzhou 16
Mirabella Eclano 16
Zhengzhou 16
Taiyuan 15
Kilburn 14
Hangzhou 13
Hebei 13
Amsterdam 12
Rome 12
Saint Petersburg 12
Dublin 11
Falls Church 11
Tianjin 11
Acton 10
Changsha 10
Hounslow 10
Montemiletto 10
Copenhagen 9
Fuzhou 9
Los Angeles 9
Seongnam-si 9
Chicago 8
Matawan 8
Ningbo 8
Seo-gu 8
Islington 7
Nürnberg 7
Wandsworth 7
Avellino 6
Dallas 6
Dongjak-gu 6
Miami 6
Naples 6
Redwood City 6
Salerno 6
San Jose 6
Frankfurt am Main 5
Haikou 5
Lanzhou 5
Milan 5
New Bedfont 5
Sofia 5
Stockholm 5
Sydney 5
Taizhou 5
Vienna 5
Xian 5
Zagreb 5
Brisbane 4
Budapest 4
Chieti 4
Florence 4
Groningen 4
Istanbul 4
Lisbon 4
Madrid 4
Panama City 4
Paris 4
Phoenix 4
Totale 21.832
Nome #
Il microinfusore: quali indicazioni e quando iniziare 413
Sussidio didattico per gli studenti di igiene generale e applicata per il corso di laurea in scienze del servizio sociale 252
The good and bad effects of statins on insulin sensitivity and secretion 207
High prevalence of endocrine dysfunction in long-term survivors after allogeneic bone marrow transplantation for hematologic diseases. 193
Berberine improves reproductive features in obese Caucasian women with polycystic ovary syndrome independently of changes of insulin sensitivity 191
Secrezioni ormonali ectopiche 189
Cardiopulmonary impairment in young women with polycystic ovary syndrome. 177
Cardiological aspects of growth hormone and insulin-like growth factor-I. 175
Effects of physical exercise on the female reproductive system. 169
Gonadal status in reproductive age women after haematopoietic stem cell transplantation for haematological malignancies. 168
Abnormal heart rate recovery after maximal cardiopulmonary exercise stress testing in young overweight women with polycystic ovary syndrome. 168
Current Insights Into Inositol Isoforms, Mediterranean and Ketogenic Diets for Polycystic Ovary Syndrome: From Bench to Bedside. 168
Effects of neridronate treatment in elderly women with osteoporosis 161
Height, weight, height velocity of primary school population sample in Campania region. 161
Early impairment of endothelial structure and function in young normal-weight women with polycystic ovary syndrome 159
Could the Mediterranean diet be effective in women with polycystic ovary syndrome? A proof of concept. 159
Low 25 (OH) vitamin D levels are associated with autoimmune thyroid disease in polycystic ovary syndrome 158
Adrenal adenoma and normal androgen levels in a young woman with polycystic ovaries: a case of idiopathic hirsutism? 157
Endocrine secretions under abnormal light-dark cycles and in the blind. 156
Effectiveness of combined GnRH analogue plus raloxifene administration in the treatment of uterine leiomyomas: a prospective, randomized, single-blind, placebo-controlled clinical trial. 155
Failure of long-term therapy with sodium valproate in Cushing's disease. 154
THE IMPACT OF PROBAND GLUCOSE TOLERANCE STATUS ON BODY MASS INDEX (BMI) AND ADIPOSITY IN ADOLESCENT GIRLS AT HIGH RISK FOR POLYCYSTIC OVARY SYNDROME (PCOS) 153
Gonadotropin-releasing hormone agonist with or without raloxifene: effects on cognition, mood and quality of life 152
Evidence-based and potential benefits of metformin in the polycystic ovary syndrome: a comprehensive review 152
Growth hormone secretion after baclofen administration in different phases of menstrual cycle in healthy women. 151
The impact of vitamin D deficiency on patients undergoing kidney transplantation: focus on cardiovascular, metabolic, and endocrine outcomes. 150
Bisphenol A in Polycystic Ovary Syndrome and its Association with Liver-Spleen Axis. 149
The increase of leukocytes as a new putative marker of low- grade chronic inflammation and early cardiovascular risk in polycystic ovary syndrome 149
Hypothalamic-pituitary-gonadal axis function after successful kidney transplantation in men and women 149
Raloxifene administration in women treated with gonadotropin-releasing hormone agonist for uterine leiomyomas: effects on bone metabolism. 149
Visceral fat is associated with cardiovascular risk in women with polycystic ovary syndrome. 149
Homocysteine levels and C677T polymorphism of methylenetetrahydrofolate reductase in women with polycystic ovary syndrome 149
GH and IGF-I deficiency are associated with reduced loss of fat mass after laparoscopic-adjustable silicone gastric banding. 148
Oral contraceptives versus physical exercise on cardiovascular and metabolic risk factors in women with polycystic ovary syndrome: a randomized controlled trial 148
Laparoscopic ovarian diathermy vs clomiphene citrate plus metformin as second-line strategy for infertile anovulatory patients with polycystic ovary syndrome: a randomized controlled trial 147
The Risk of a Persistent Glucose Metabolism Impairment After Gestational Diabetes Mellitus Is Increased in Patients With Polycystic Ovary Syndrome 147
Endothelial dysfunction in PCOS: role of obesity and adipose hormones. 147
Growth hormone status in morbidly obese subjects and correlation with body composition 146
A randomized controlled trial evaluating metformin pre-treatment and co-administration in non-obese insulin-resistant women with polycystic ovary syndrome treated with controlled ovarian stimulation plus timed intercourse or intrauterine insemination. 146
The cardiovascular risk of young women with polycystic ovary syndrome: an observational, analytical, prospective case-control study 146
Beneficial treatment with risedronate in long-term survivors after allogeneic stem cell transplantation for hematological malignancies. 145
How to manage the reproductive issues of PCOS: a 2015 integrated endocrinological and gynecological consensus statement of the Italian Society of Endocrinology. 145
Prevalence of polycystic ovary morphology in a region of South Italy. 145
Current evidence on vitamin D deficiency and kidney transplant: What’s new? 145
Report on the Third Annual Meeting of the Androgen Excess Society, San Diego, California, June 3, 2005 144
Human prostatic cell line PNT1A, a useful tool for studying androgen receptor transcriptional activity and its differential subnuclear localization in the presence of androgens and antiandrogens. 144
Circulating ghrelin concentrations in the polycystic ovary syndrome 144
Effect of preconceptional metformin on abortion risk in polycystic ovary syndrome: a systematic review and meta-analysis of randomized controlled trials 144
Efficacy of laparoscopic ovarian diathermy in clomiphene citrate-resistant women with polycystic ovary syndrome: relationships with chronological and ovarian age 143
Effect of estrogen replacement plus low-dose alendronate treatment on bone density in surgically postmenopausal women with osteoporosis. 142
Antisperm antibodies in cryptorchidism before and after surgery. 142
Lifestyle changes in the management of adulthood and childhood obesity. 142
Beneficial effects of a three-month structured exercise training program on cardiopulmonary functional capacity in young women with polycystic ovary syndrome. 142
Ovulation induction in polycystic ovary syndrome 141
Screening a coastal population in Southern Italy: iodine deficiency and prevalence of goitre, nutritional aspects and cardiovascular risk factors 141
Liver-spleen axis, Insulin-like Growth Factor-(IGF)-I axis and fat mass in overweight/obese females 141
Effect of growth hormone on cardiac function. 140
Auditory brainstem responses in thyroid diseases before and after therapy. 140
Role of dehydroepiandrosterone sulfate levels on body composition after laparoscopic adjustable gastric banding in pre-menopausal morbidly obese women 140
Polycystic ovary syndrome (PCOS) trilogy: a translational and clinical review 140
Growth rate and growth hormone response to growth hormone-releasing hormone challenge in slowly growing children during chronic administration of clonidine. 139
Terapia di associazione con insulina ed analoghi del GLP-1 139
Are serum adiponectin levels really reduced in obese women with polycystic ovary syndrome? 139
Clomiphene citrate, metformin or both as first-step approach in treating anovulatory infertility in patients with polycystic ovary syndrome (PCOS): a systematic review of head-to-head randomized controlled studies and meta-analysis 138
Lymphocyte subset pattern in acromegaly. 138
Clinical use of the perifollicular vascularity assessment in IVF cycles: a pilot study 138
Is the ovulation induction still a therapeutic problem in patients with polycystic ovary syndrome? 137
Insulin resistance in postmenopausal women with metabolic syndrome and the measurements of adiponectin, leptin, resistin, and ghrelin 137
Growth hormone treatment prevents loss of lean mass after bariatric surgery in morbidly obese patients: results of a pilot, open, prospective, randomized, controlled study 136
Metformin administration and laparoscopic ovarian drilling improve ovarian response to clomiphene citrate (CC) in oligo-anovulatory CC-resistant women with polycystic ovary syndrome 136
Endocrinopathies after allogeneic and autologous transplantation of hematopoietic stem cells. 136
Cardiovascular risk of women with polycystic ovary syndrome 136
Inflammatory markers and visceral fat are inversely associated with maximal oxygen consumption in women with polycystic ovary syndrome (PCOS) 135
Serum 25-Hydroxyvitamin D Levels, phosphoprotein enriched in diabetes gene product (PED/PEA-15) and leptin-to-adiponectin ratio in women with PCOS 135
Vitamin D and thyroid disease: to D or not to D? 135
Letter to the Editor: Vitamin D: A Wonder Drug for the Cure of Type 2 Diabetes? 135
Growth hormone secretion after baclofen administration in different phases of menstrual cycle in healthy women 133
Raloxifene administration in premenopausal women with uterine leiomyomas: a pilot study. 133
Is plasminogen activator inhibitor-1 a cardiovascular risk factor in young women with polycystic ovary syndrome? 133
Early carotid atherosclerosis in normotensive severe obese premenopausal women with low DHEA(S). 133
Anti-proliferative and pro-apoptotic effects of raloxifene on uterine leiomyomas in postmenopausal women 132
Efficacy of risedronate administration in osteoporotic postmenopausal women affected by inflammatory bowel disease 132
Mechanisms in endocrinology: vitamin D as a potential contributor in endocrine health and disease. 132
Low serum vitamin D-status, air pollution and obesity: A dangerous liaison. 132
Systemic and local effects of metformin administration in patients with polycystic ovary syndrome (PCOS): relationship to the ovulatory response 132
Clomiphene citrate versus metformin as first-line approach for the treatment of anovulation in infertile patients with polycystic ovary syndrome 131
Thyroid function and morphology after a successful kidney transplantation 131
Adrenal mass: insight into pathogenesis and a common link with insulin resistance. 131
Vitamin D and pancreas: the role of sunshine vitamin in the pathogenesis of Diabetes Mellitus and Pancreatic Cancer. 131
Does metformin affect ovarian morphology in patients with polycystic ovary syndrome? A retrospective cross-sectional preliminary analysis 131
Leuprolide acetate treatment with and without coadministration of tibolone in premenopausal women with menstrual cycle-related irritable bowel syndrome 130
Gut: a key player in the pathogenesis of type 2 diabetes? 130
Does raloxifene inhibit the growth of uterine fibroids? 129
Evidence for altered adipocyte function in polycystic ovary syndrome. 129
Uterine effects of metformin administration in anovulatory women with polycystic ovary syndrome 129
Visceral fat and cardiovascular risk in patients with polycystic ovary syndrome. 129
Endocrine Aspects of Environmental "Obesogen" Pollutants. 129
Cardiopulmonary impairment in young women with polycystic ovary syndrome 128
Abdominal fat quantity and distribution in women with polycystic ovary syndrome and extent of its relation to insulin resistance 128
Metformin reduces risk of ovarian hyperstimulation syndrome in patients with polycystic ovary syndrome during gonadotropin-stimulated in vitro fertilization cycles: a randomized, controlled trial. 128
Totale 14.892
Categoria #
all - tutte 89.725
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 89.725


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/20191.641 0 0 0 0 0 0 0 0 0 349 697 595
2019/20208.289 574 644 631 1.933 908 786 1.035 606 564 136 424 48
2020/20214.882 395 96 438 184 618 96 525 37 124 440 129 1.800
2021/20222.163 139 314 34 771 76 45 253 199 141 116 69 6
2022/20234.290 523 136 215 458 498 796 115 566 571 120 223 69
2023/20241.040 134 71 77 54 54 34 25 316 268 7 0 0
Totale 29.669